Treatment Of Pityriasis Versicolor Research Articles

Observation on the Clinical Efficacy of Integrated Traditional Chinese and Western Medicine in the Treatment of Pityriasis Versicolor

Observation on the Clinical Efficacy of Integrated Traditional Chinese and Western Medicine in the Treatment of Pityriasis Versicolor

Efficacy of Combination of Topical Ketoconazole 2% Cream and Adapalene 0.1% Gel versus Topical Ketoconazole 2% Cream Alone in Treatment of Pityriasis Versicolor

Pityriasis Versicolor (PV) is a superficial skin infection caused by Malassezia yeasts, resulting in hypo and hyperpigmented macules. It affects up to 40% of individuals, often leading to itching, decreased quality of life, and social stigma. Objective: To compare the efficacy of combination of topical ketoconazole 2% cream and adapalene 0.1% gel versus topical ketoconazole 2% cream alone in treatment of pityriasis versicolor. Methods: A comparative cross-sectional study was conducted at the Department of Dermatology, Nishtar Hospital, Multan, spanning from November 2020 to April 2021. Total 90 patients were divided equally into two groups: Group A received a combination of Ketoconazole 2% cream and adapalene 1% gel, while Group B received Ketoconazole 2% cream alone. The efficacy of both treatments was evaluated and compared. The study utilized SPSS version 26.0 for data analysis. Results: In terms of gender, 52.22% were male, and 47.78% were female across both groups. The mean duration of the disease was 5.84 ± 3.26 years in Group A and 6.04 ± 3.11 years in Group B, with an overall mean of 5.95 ± 3.17 years. The efficacy of Group A was 91.11%, with 41 participants showing positive results, while Group B had an efficacy of 75.56%, with 34 participants showing positive results. Conclusions: The study findings indicate that using a combination of adapalene 0.1% gel and ketoconazole 2% cream is more efficacious than using ketoconazole 2% cream alone in treating PV

Comparison of Efficacy of Single Oral Dose Fluconazole Versus Single Oral Dose Itraconazole in Patients with Pityriasis Versicolor

Objective: To compare the efficacy of single oral dose Fluconazole and Itraconazole in patients with Pityriasis Versicolor. Methodology: This Randomized control trial study was conducted at the Department of Dermatology, Combined Military Hospital, Abbottabad, Pakistan from March 2022 to August 2022. A total of 60 patients coming to OPD of derma department and diagnosed with Tinea Versicolor were randomized in 2 equal groups of 30 patients each. Patients diagnosed on odd serial number were allocated to group A and were prescribed oral Fluconazole (400 mg stat) while patients diagnosed on even serial number were allocated to group B and were prescribed oral Itraconazole (1000 mg stat). Diagnosis was made clinically and then by using mycological tests. Follow up visits were made at completion of 2nd and 4th weeks of start of treatment. Primary outcome was set as efficacy of the treatments at completion of 4 weeks that was assessed using mycological tests. Results: In this study, age ranged was from 19 to 40 years with mean age of 30.066±7.74 years. Mean duration of disease was 4.216±1.29 months. At completion of study (4 weeks), treatment was effective in 25 patients (83.33%) in group A while in 17 patients (56.6%) in group B with a significant difference in efficacy between two groups (p=0.024). There was a good tolerability in both groups without any serious adverse reactions reported. Conclusion: Single oral dose of Fluconazole is more effective compared to single oral dose of Itraconazole in the treatment of Pityriasis Versicolor.

Efficacy of Azoles Antifungals in Treatment of Pityriasis Versicolor

Introduction: Pityriasis versicolor is superficial fungal infection. Topical drugs are often effective in treatment of limited disease while systemic drugs are more suitable in extensive cases. The systemic triazole drugs, itraconazole and fluconazole have shown promising results at different doses.
 Aims: To assess the efficacy and safety of oral fluconazole combined with ketoconazole shampoo and oral itraconazole in the treatment of Pityriasis versicolor.
 Methods: The study was conducted at department of Dermatology at Nepalgunj Medical College from March 2019 to February 2020. Total 100 patients of both genders with Pityriasis versicolor were randomly allocated into two groups with 50 patients in each group. Patients in Group I received oral fluconazole 300mg a week for two consecutive weeks along with ketoconazole 2% shampoo twice weekly for two weeks while those in Group II received itraconazole 200mg daily for one week. Efficacy was assessed in terms of negative fungal hyphae. The drug is considered safe if no patients were withdrawn for clinical adverse effects or laboratory abnormalities.
 Results: In this study age ranged from 18 to 50 years with mean age of 31.1 years in Group I and 31.92 years in Group II. Efficacy was seen in 78% of Group I patients as compared to 54% in Group II patients at two weeks and 94% in Group I and 90% in Group II at four weeks. No significant adverse effects were reported in any of the group.
 Conclusion: Fluconazole along with ketoconazole shampoo is more effective than itraconazole in treatment of pityriasis versicolor with minimal side effects, at lesser cost.

Ketoconazole 2% cream versus a combination of ketoconazole 2% cream and adapalene 0.1% gel in the treatment of pityriasis versicolor

Background and aim Pityriasis versicolor is a common chronic superficial fungal infection that manifests during or after puberty in hot humid temperatures. Topical treatments, which are the first line of treatment, are divided into nonspecific and specific antifungal agents; however, the therapeutic approaches for pityriasis versicolor depend mainly on synthetic antifungal drugs, in particular ketoconazole. However, due to the frequent recurrence of this disease, and the widespread application of azole drugs, resistant strains have emerged leading to increasingly failed treatment rates. Retinoic acid creams are also effective against pityriasis versicolor. Especially adapalene gel that has less irritation compared with other topical retinoid products and also has rapid onset of action. Therefore, we aimed to evaluate the efficacy and safety of a combination treatment of ketoconazole cream 2% and adapalene gel 0.01% in the treatment of pityriasis versicolor. Patients and methods In all, 100 patients were divided equally into two groups: group 1 patients were treated with topical application ketoconazole 2% cream and adapalene 0.1% gel once daily for a total duration of 2 weeks. Group 2 patients were treated with a topical application ketoconazole 2% cream for a total duration of 2 weeks. Results There was significant improvement rates in the combined group than ketoconazole-only group with P value=0.023. Adepalene+ketoconacole group had more irritation as a side effect than the ketoconazole group with significant P value=0.001. Conclusion The combination of adapalene 0.1% gel and ketoconazole 2% cream is safe, rapid, and effective in the treatment of pityriasis versicolor.

Pentas longiflora Oliv. (Rubiaceae), a plant used in the treatment of Pityriasis Versicolor in Rwanda: Chemical composition and standardization of leaves and roots

In Rwanda, the roots of Pentas longiflora Oliv. (Rubiaceae) have been used for a long time to treat Pityriasis versicolor. However, many people reported the use of leaves instead of roots. This research was conducted to compare the phytochemical composition and establish chromatographic methods for the standardization of roots and leaves extracts of P. longiflora. During this process, three new pentalongin glycosides (pentalonginoside A, pentalonginoside B, and pentalonginoside C) and two known glycosides of the same type (harounoside and clarinoside), as well as rutin, luteolin-7-rutinoside were isolated from methanol extract of leaves. In addition, pentalongin and psychorubrin, previously isolated from ethylacetate roots extract, were also identified in Pentas longiflora ethylacetate leaves extract. The presence of the antifungal compound pentalongin in leaves may explain the traditional use of leaves in the treatment of Pytiriasis versicolor.Furthermore, harounoside, psychorubrin, and pentalongin were selected as markers for HPLC fingerprints of MeOH extract. The accuracy and risk profile demonstrated the reliability of the validated method. In general, considerable variations of concentration in plant metabolites, including pentalongin, were observed between samples from different sites. The content in pentalongin (expressed as juglone) in collected samples ranged between 1.7 and 70.0 mg/100 g. The highest concentration (70.0 ± 17 mg/100 g) was registered in the cultivated samples from Mukoni.This important variation of pentalongin concentrations according to sampling sites, shows that in order to guarantee equivalent efficacy, finished products with P. longiflora should be standardized based on their pentalongin content.

COMPARATIVE EFFICACY OF ORAL FLUCONAZOLE AND ORAL ITRACONAZOLE IN PITYRIASIS VERSICOLOR

Objective: To compare the efficacy of oral fluconazole and oral itraconazole in the treatment of Pityriasisversicolor.
 Study Design: Comparative prospective study.
 Methodology: Total 72 patients of both genders with Pityriasis versicolor were included. Patients were randomly allocated into two treatment groups with 36 patients in each group: group A and group B by lottery method. Patients in group A received Cap Fluconazole 150 mg bi- weekly for two consecutive weeks while those in group B received two doses of 400 mg of itraconazole once weekly for two weeks. Patients were asked to follow-up after 4 weeks skin scrapings for microscopy using 10% KOH mount was done at follow-up. Efficacy was assessed in terms of negative fungal hyphae on microscopy.
 Results: In this study, age ranged from 18 to 40 years with mean age of 33.52 ± 4.12 years in group A, whereas35.055 ± 4.18 years in group B. Mean duration of disease was 4.66 ± 1.51 months in group A and 5.27 ± 1.70months in group B. Efficacy was seen in 77.8% of group A patients as compared to 50% in group B patients(p=0.014).
 Conclusion: Oral Fluconazole two doses of 150 mg/week (total 300mg/week) for two consecutive weeks wasfound more effective than oral itraconazole.

Adapalene gel 0.1% vs ketoconazole cream 2% and their combination in treatment of pityriasis versicolor: A randomized clinical study.

Pityriasis versicolor (PV) is a chronic superficial fungal infection. Management using azole drugs leads to drug resistance. The present study aimed to compare the clinical outcome of 0.1% adapalene gel vs 2% ketoconazole cream and their combination in PV. This randomized double-blinded study was conducted on 90 PV patients divided into three equal groups. GI was treated with topical ketoconazole 2% cream twice daily and placebo, GII was treated with topical 0.1% adapalene gel twice daily and placebo and GIII was treated with topical combination of 0.1% adapalene gel (at night) and ketoconazole 2% cream (in the morning). All patients received medications for 4 weeks. Evaluation was done at 2 and 4 weeks and included clinical assessment, laboratory assessment, and patient satisfaction. We found that after 4 weeks of treatment, all groups showed significant improvement. There was better response in GIII in terms of lower rate of positive potassium hydroxide staining, higher rate of significantly improved cases and higher rate of well-satisfied patients. However, the difference fell short of statistical significance. We concluded that a combination of adapalene gel and ketoconazole cream is very effective in treatment of PV with no or mild side effects.

Comparative assessment of therapeutic efficacy of topical luliconazale versus topical ketoconazole in the treatment of pityriasis versicolor

Comparative assessment of therapeutic efficacy of topical luliconazale versus topical ketoconazole in the treatment of pityriasis versicolor

The value of diclofenac gel 1 % in the treatment of pityriasis versicolor in a sample of Iraqi patients

The value of diclofenac gel 1 % in the treatment of pityriasis versicolor in a sample of Iraqi patients

Efficacy of Azole Antifungal in Treatment of Pityriasis Versicolor.

AIM:Compare itraconazole alone, fluconazole combined with ketoconazole and ketoconazole in the treatment of patients with pityriasis versicolor.MATERIAL AND METHODS:A group of 240 pityriasis versicolor patients (confirmed with KOH and culture) were classified into 3 groups: Fluconazole 300 mg a week and 2% ketoconazole foam twice a week for 2 weeks (Category I), Itraconazole 200 mg daily for one week (category II); Ketoconazole 2% foam daily for 2 weeks (Category 3). Clinical (colour of macule, scale, pruritus) and mycological assessment were done after 4 weeks of therapy.RESULTS:After 4 weeks of treatment, clinical cure was observed in 62.4% (Category I), 36.3% (Category II) and 37.5% (Category III).CONCLUSION:It was reported in our study that the most effective regimen for PV patients is fluconazole 300 mg per week combined with ketoconazole 2% twice a week for 2 weeks.

Interventions for the treatment of pityriasis versicolor

Interventions for the treatment of pityriasis versicolor

Comparison of Topical ketoconzole alone versus Topical Ketoconazole plus Topical Adapalene in the Treatment of Patients with Pityriasis Versicolor

Background& Objectives: Pityriasis Versicolor (PV) is a chronic cutaneous fungal infection caused by Malassezia species. A recent study showed combination therapy consisting of Ketoconazole plus Adapalene gel to be superior to Ketoconazole monotherapy. The objective of this study was to compare the frequency of patients improved with Ketoconazole alone versus Ketoconazole plus Adapalene in the treatment of Pityriasis Versicolor. Study design: Randomized controlled trial. Place & duration of study: Department of Dermatology, CMH Lahore from 20th May 2016 to 19th November 2016. Methods: This study included 80 patients, both male and female, aged between 18 -70 yrs presenting with Pityriasis Versicolor. These patients were divided into two treatment groups. Randomly Patients in Group-A were given Ketoconazole cream alone while patients in GroupB were given combination therapy with Ketoconazole cream plus Adapalene gel applied separately with different timings. Outcome variable was number of patients improved after 2 weeks of treatment. Results: The frequency of improvement at 2 weeks was significantly higher with the combination therapy (87.5% vs. 47.5%; p=0.000) as compared to Ketoconazole alone and this difference was significant across all age, gender and duration of disease groups. Conclusion: The frequency of improvement was significantly higher with the combination therapy consisting of Ketoconazole plus Adapalene as compared to Ketoconazole alone, advocating preferred use of combination therapy in patients presenting with Pityriasis Versicolor in future practice.

Naftifine hydrochloride (NH) in the treatment of pityriasis versicolor

Introduction & objectives: The purpose of this study was to demonstrate the efficacy comparability of 1% NH lotion vs. of 1% NH cream (exoderil, Sandoz) in the treatment of pityriasis versicolor. Material & methods. 71 patients with pityriasis versicolor were randomly allocated either to receive NH lotion once daily (NH lotion group (п = 35, 38.6 years (95% CI [33,7, 43.5]) or NH cream once daily (NH cream group (п = 36, 40.8 years (95% CI [36,6, 45.0]) for 14 days. Mycological evaluations (microscopy and culture) were performed at weeks 2 and 3, inflammation symptoms evaluations were scored at day 3, weeks 2 and 3 after start of the therapy. Overall cure rates assessment included results of mycological, clinical outcomes and safety evaluation. Results. There was no difference between groups in mycological cure rates (94% vs 92%) and inflammation regression (97% vs 97%). Overall cure rate was 91% and 92% of patients in NH lotion and NH cream groups respectively (p = 0,97). Conclusion. 1% NH lotion and 1% NH cream are effective in the treatment of pityriasis versicolor.

A Comparative Study of Efficacy, Safety and Relapse Rate of Three Drugs; Systemic Ketoconazole, Systemic Itraconazole and Topical Oxiconazole in the Treatment of Pityriasis Versicolor

Aim : The aim of our study was to evaluate the efficacy, safety and relapse rate of systemic Ketoconazole, systemic Itraconazole and topical Oxiconazole in the treatment of pityriasis versicolor. Study design : 94 patients who had pityriasis versicolor were included in the study. The patients were given Ketoconazole, Itraconazole and Oxiconazole randomly and were followed up at the interval of 15 days, 1 month and 3 months for assessement of clinical and mycological cure. Results : In assessment of clinical parameters maximum improvement in scaling, pigmentation and pruritus was seen in Oxiconazole group compared to itraconazole and ketoconazole group. During the study it was observed that rate of clinical cure was maximum in Oxiconazole group (76.67%) as compared to Itraconazole (58.82%) and Ketoconazole group (46.66%). Mycological cure during visit 2 in Oxiconazole group was (83.33%), as compared to (88.2%) Itraconazole group and (88.7%) Ketoconazole group. During visit 3, mycological cure was present in 93.3% cases in Oxiconazole group, 94.1% in Itraconazole group and 93.3% in Ketoconazole group. During visit 4 mycological cure was assessed which showed 88.7% cure rate in Oxiconazole group compared to 88.2% in Itraconazole group and 88.7% in Ketoconazole group. These results suggested presence of relapse in 6.6% cases in both Oxiconazole and Ketoconazole group and 5.9% cases in Itraconazole group. There were no side effects with oxiconazole group while cases treated with ketoconazole and itraconazole had side effects like nausea and urticaria. Conclusion : According to the present study we conclude that topical Oxiconazole therapy was more effective as compared to systemic Itraconazole and Ketoconazole therapy in early improvement of scaling, pigmentation and pruritus secondary to Pityriasis versicolor with no significant side effects.

A Comparative Study of Efficacy, Safety and Relapse Rate of Three Drugs; Systemic Ketoconazole, Systemic Itraconazole and Topical Oxiconazole in the Treatment of Pityriasis Versicolor

<strong>Aim</strong>: The aim of our study was to evaluate the efficacy, safety and relapse rate of systemic Ketoconazole, systemic Itraconazole and topical Oxiconazole in the treatment of pityriasis versicolor. <strong>Study design</strong>: 94 patients who had pityriasis versicolor were included in the study. The patients were given Ketoconazole, Itraconazole and Oxiconazole randomly and were followed up at the interval of 15 days, 1 month and 3 months for assessement of clinical and mycological cure. <strong>Results</strong>: In assessment of clinical parameters maximum improvement in scaling, pigmentation and pruritus was seen in Oxiconazole group compared to itraconazole and ketoconazole group. During the study it was observed that rate of clinical cure was maximum in Oxiconazole group (76.67%) as compared to Itraconazole (58.82%) and Ketoconazole group (46.66%). Mycological cure during visit 2 in Oxiconazole group was (83.33%), as compared to (88.2%) Itraconazole group and (88.7%) Ketoconazole group. During visit 3, mycological cure was present in 93.3% cases in Oxiconazole group, 94.1% in Itraconazole group and 93.3% in Ketoconazole group. During visit 4 mycological cure was assessed which showed 88.7% cure rate in Oxiconazole group compared to 88.2% in Itraconazole group and 88.7% in Ketoconazole group. These results suggested presence of relapse in 6.6% cases in both Oxiconazole and Ketoconazole group and 5.9% cases in Itraconazole group. There were no side effects with oxiconazole group while cases treated with ketoconazole and itraconazole had side effects like nausea and urticaria. <strong>Conclusion</strong>: According to the present study we conclude that topical Oxiconazole therapy was more effective as compared to systemic Itraconazole and Ketoconazole therapy in early improvement of scaling, pigmentation and pruritus secondary to Pityriasis versicolor with no significant side effects.

A randomized double-blind, non-inferiority Phase II trial, comparing dapaconazole tosylate 2% cream with ketoconazole 2% cream in the treatment of Pityriasis versicolor

Objectives: The objective of this research was to evaluate the efficacy of a new antifungal imidazole, dapaconazole tosylate, in the treatment of Pityriasis versicolor (PV).Design and methods: Sixty patients with clinical and mycological diagnosis of PV were randomly assigned to receive either 1 g dapaconazole tosylate 2% cream or 1 g ketoconazole 2% cream. Treatments were applied once a day for 28 days. A dermatologist evaluated efficacy and safety daily, and weekly laboratorial tests were performed. The primary end point was a clinical and mycological cure of lesions after 28 days of treatment. The secondary end point was the time to clinical healing assessed by Kaplan–Meier analysis and Log-rank testing.Results: Fifty-three patients adhered to protocol rules. Clinical and mycological cure was achieved in 84.6% (22/26) and 92.6% (25/27) of patients treated with ketoconazole and dapaconazole, respectively (difference [effect size] = 8.0%, Standard error of difference: 8.69%, 95% CI: –6.3 to 22.3%). Median time to healing was 23.5 and 21 days for ketoconazole and dapaconazole, respectively (p = 0.126). Adverse events occurred only in ketoconazole-treated patients (13%; 4/30).Conclusion: Dapaconazole tosylate is non-inferior to ketoconazole when used at a dose of 20 mg/day for 28 consecutive days for the treatment of PV. Dapaconazole also demonstrated a good safety profile.

Interventions for the treatment of pityriasis versicolor

Interventions for the treatment of pityriasis versicolor

A randomized controlled trial of combination treatment with ketoconazole 2% cream and adapalene 0.1% gel in pityriasis versicolor

Background: Ketoconazole cream and adapalene gel are effective drugs against pityriasis versicolor. However, there are no reports on combination treatment with both compounds in pityriasis versicolor. Objective: To evaluate the efficacy and safety of combination therapy with adapalene 0.1% gel and ketoconazole 2% cream against pityriasis versicolor. Methods: Participants with pityriasis versicolor were randomly assigned to two groups: the combination group was treated with adapalene 0.1% gel and ketoconazole 2% cream once daily, and the monotherapy group received ketoconazole 2% cream twice daily. The treatment lasted 2 weeks in both groups. Outcomes were assessed at baseline and 1, 2 and 4 weeks after the initiation of treatment. Results: We noted clinically significant differences in total improvement rates between groups Weeks 1 and 2. A statistically significant difference was obtained Week 4. The treatment was well tolerated by all participants. Conclusions: The combination of adapalene 0.1% gel and ketoconazole 2% cream is effective and safe in the treatment of pityriasis versicolor. This therapeutic regimen was rapid, providing a valuable option for patients with pityriasis versicolor.

Treatment of pityriasis versicolor with topical application of essential oil of Cymbopogon citratus (DC) Stapf - therapeutic pilot study

BACKGROUND Pityriasis versicolor is a fungal infection caused by Malassezia spp. that has frequent relapses. OBJECTIVES The main objective of this research was to perform phase I and II clinical studies, using formulations containing essential oil of Cymbopogon citratus in patients with pityriasis versicolor. METHODS Phase I study included twenty volunteers to ascertain the safety of the formulations. In phase II, 47 volunteers randomly received essential oil formulations at 1.25 μL/mL concentration, for forty days. The shampoo should be applied three times a week and the cream twice a day. A control group in phase II, consisting of 29 volunteers, received the same formulations but with 2% ketoconazole as the active ingredient. RESULTS No significant adverse events were observed in volunteers during Phase I. In Phase II, 30 (63.83%) volunteers using essential oil and 18 (62.07%) using ketoconazole remained until the end of the study. We observed a predominance of lesions in disseminated form, with M. sympodialis detected as the predominant agent identified in cultures. After 40 days of treatment, the rate of mycological cure was 60% (p <0.05) for the group treated with essential oil of C. citratus and over 80% (p <0.05) for the group treated with ketoconazole formulations. CONCLUSIONS Notwithstanding the safety and antifungal effects observed in this study after application of formulations containing the essential oil of C. citratus, further studies with larger populations should be performed to confirm the actual potential of these formulations in the treatment of patients with Pityriasis versicolor.